We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Activity Monitoring Assessment of Opiate Withdrawal - 4

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000335
First Posted: September 21, 1999
Last Update Posted: January 31, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Washington D.C. Veterans Affairs Medical Center
Information provided by:
National Institute on Drug Abuse (NIDA)
  Purpose
The purpose of this study is to determine if hyperactivity accompanies abrupt opiate withdrawal in heroin addicts, to determine if computerized solid state activity monitors are capable of quantifying hyperactivity, and to quantify the physical and affective symptoms occurring during abrupt withdrawal in heroin addicts and morphine's capacity to alleviate these symptoms.

Condition Intervention Phase
Opioid-Related Disorders Drug: Morphine Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Activity Monitoring Assessment of Opiate Withdrawal

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Depression
  • Anxiety
  • Withdrawal severity
  • Activity
  • Opiate secondary withdrawal

Estimated Enrollment: 0
Actual Study Start Date: September 30, 1995
Study Completion Date: May 20, 1996
Primary Completion Date: March 20, 1996 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000335


Locations
United States, District of Columbia
Washington DC VA
Washington, District of Columbia, United States, 20422
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Washington D.C. Veterans Affairs Medical Center
Investigators
Principal Investigator: Steven Deutsch, M.D. Washington D.C. Veterans Affairs Medical Center
  More Information

Publications:
1996 CPDD, NIDA Research Monograph

ClinicalTrials.gov Identifier: NCT00000335     History of Changes
Other Study ID Numbers: NIDA-3-0009-4
Y01-3-0009-4
First Submitted: September 20, 1999
First Posted: September 21, 1999
Last Update Posted: January 31, 2017
Last Verified: December 2002

Keywords provided by National Institute on Drug Abuse (NIDA):
opioid dependence

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Morphine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents